Calcitriol Soft Capsules

The main ingredient of this product is calcitriol.

1. Postmenopausal osteoporosis; 2. Chronic renal insufficiency; 3. Postoperative hypothyroidism; 4. Idiopathic hypoparathyroidism; 5. Pseudohypothyroidism; 6. Vitamin D-dependent rickets; 7. Hypophosphatemic vitamin D-resistant rickets, etc.

The optimal daily dose of this product should be carefully determined according to the serum calcium level of each patient. When starting treatment with this product, the lowest dose possible should be used, and the dose should not be increased without monitoring the serum calcium level. The optimal daily dose of this product should be carefully determined according to the serum calcium level of each patient. When starting treatment with this product, the lowest dose possible should be used, and the dose should not be increased without monitoring the serum calcium level. After determining the optimal dose of this product, the serum calcium level should be checked monthly (or refer to the detailed instructions for individual indications below). When collecting serum calcium samples, a tourniquet should not be used. If the serum calcium exceeds the normal range (9-11mg/100ml or 2250-2750μmol/l) by 1mg/100ml (250μmol/l), or the serum creatinine is greater than 120μmol/l, the dose must be reduced or treatment must be completely discontinued until the serum calcium is normal. During the period of increasing serum calcium, serum calcium and phosphorus levels must be measured daily. This product can be taken after the blood calcium returns to normal, but the daily dose should be 0.25μg lower than the previous dose. The daily calcium intake should be estimated and adjusted as appropriate. A prerequisite for the best efficacy of this product is sufficient but not excessive calcium intake (adults: about 800 mg per day). Calcium supplementation is necessary at the beginning of treatment. Because of the improvement in calcium absorption by the gastrointestinal tract, some patients may need to maintain a lower calcium intake. Patients with a tendency to hypercalcemia may only need a small dose of calcium supplementation and no calcium supplementation at all. The total daily calcium intake (such as from food and medicine) is about 800mg on average and should not exceed 1000mg. Oral administration, the specific method is as follows: 1

Since calcitriol can produce the effects of vitamin D, the adverse reactions that may occur are similar to those of vitamin D overdose. Such as hypercalcemia syndrome or calcium poisoning (depending on the severity and duration of hypercalcemia). Occasional acute symptoms include loss of appetite, headache, vomiting and constipation. Chronic symptoms include malnutrition, sensory impairment, fever with thirst, polyuria, dehydration, emotional indifference, developmental arrest and urinary tract infection. This product has been used clinically for up to 15 years to treat all indications. The results showed that the incidence of adverse reactions was very low, including hypercalcemia, with an incidence of 0.111% or less. Patients with concurrent hypercalcemia and hyperphosphatemia (concentration greater than 6mg/100mmol/l) may develop soft tissue calcification, which can be observed through radiological examinations. In patients with normal renal function, chronic hypercalcemia may be associated with increased blood creatinine. Due to the short biological half-life of calcitriol, its pharmacokinetic studies have shown that elevated blood calcium returns to the normal range after discontinuation or reduction of the dose for several days, a process that is much faster than vitamin D3. Allergic reactions may occur in sensitive patients.

This product is contraindicated in patients with signs of vitamin D toxicity.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

Do not use with antacids containing magnesium.

Keep away from light and sealed.

1.0 μg

Qingdao Guoxin Pharmaceutical Co., Ltd.

• Founded in:

  1994-11-24

• Address:

  No. 3601, Tuanjie Road, Qingdao Economic and Technological Development Zone

• Tax NO.:

  91370211614316886Y

• Registered Funds:

  62.748 million yuan

• Email:

  Log in to view